File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Scopus: eid_2-s2.0-69849093757
- PMID: 19704171
- WOS: WOS:000269719200009
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy
Title | Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy |
---|---|
Authors | |
Issue Date | 2009 |
Publisher | International Medical Press. The Journal's web site is located at http://www.intmedpress.com/Journals/AVT/journals_avt_home.cfm |
Citation | Antiviral Therapy, 2009, v. 14 n. 5, p. 679-685 How to Cite? |
Abstract | Background: This study aimed to identify the baseline hepatitis B virus (HBV) DNA, alanine aminotransferase (ALT) levels and on-treatment HBV DNA levels for favourable outcome in patients receiving 5-year lamivudine. Methods: Virological, serological and biochemical parameters were assessed in 74 hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients at year 5 of therapy. Results: Patients with baseline HBV DNA levels <9 log10 copies/ml and ALT≥-2x the upper limit of normal (ULN) had a significantly higher chance of HBV DNA suppression to <4 log10 copies/ml (76.5%) and HBeAg seroconversion (82.4%), and a lower chance of YMDD mutations (35.3%) compared with patients with HBV DNA<9 log10 copies/ml and ALT<2xULN and patients with HBV DNA≥9 log10 copies/ml (all P<0.05). All patients with these two baseline parameters plus week 4 HBV DNA<4 log10 copies/ml achieved HBV DNA<35 copies/ml, HBeAg seroconversion and ALT normalization without YMDD mutations at year 5. When these two baseline parameters were combined with week 24 HBV DNA<3 log10 copies/ml, 60%, 80% and 90% of patients had HBV DNA<35 copies/ml, <3 log1'0 copies/ml and <4 log10 copies/ml, respectively at year 5. Overall, 90% of patients had HBeAg seroconversion and only 10% had YMDD mutations. Conclusions: For HBeAg-positive patients with baseline HBV DNA<9 log10 copies/ml and ALT≥2xULN, lamivudine could be initiated. For those with HBV DNA<4 log10 copies/ml at week 4 or <3 log10 copies/ml at week 24, continuation of lamivudine treatment would be more likely to result in a good long-term response. © 2009 International Medical Press. |
Persistent Identifier | http://hdl.handle.net/10722/163270 |
ISSN | 2023 Impact Factor: 1.3 2023 SCImago Journal Rankings: 0.447 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yuen, MF | en_HK |
dc.contributor.author | Fung, J | en_HK |
dc.contributor.author | Seto, WK | en_HK |
dc.contributor.author | Wong, DKH | en_HK |
dc.contributor.author | Yuen, JCH | en_HK |
dc.contributor.author | Lai, CL | en_HK |
dc.date.accessioned | 2012-09-05T05:29:24Z | - |
dc.date.available | 2012-09-05T05:29:24Z | - |
dc.date.issued | 2009 | en_HK |
dc.identifier.citation | Antiviral Therapy, 2009, v. 14 n. 5, p. 679-685 | en_HK |
dc.identifier.issn | 1359-6535 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/163270 | - |
dc.description.abstract | Background: This study aimed to identify the baseline hepatitis B virus (HBV) DNA, alanine aminotransferase (ALT) levels and on-treatment HBV DNA levels for favourable outcome in patients receiving 5-year lamivudine. Methods: Virological, serological and biochemical parameters were assessed in 74 hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients at year 5 of therapy. Results: Patients with baseline HBV DNA levels <9 log10 copies/ml and ALT≥-2x the upper limit of normal (ULN) had a significantly higher chance of HBV DNA suppression to <4 log10 copies/ml (76.5%) and HBeAg seroconversion (82.4%), and a lower chance of YMDD mutations (35.3%) compared with patients with HBV DNA<9 log10 copies/ml and ALT<2xULN and patients with HBV DNA≥9 log10 copies/ml (all P<0.05). All patients with these two baseline parameters plus week 4 HBV DNA<4 log10 copies/ml achieved HBV DNA<35 copies/ml, HBeAg seroconversion and ALT normalization without YMDD mutations at year 5. When these two baseline parameters were combined with week 24 HBV DNA<3 log10 copies/ml, 60%, 80% and 90% of patients had HBV DNA<35 copies/ml, <3 log1'0 copies/ml and <4 log10 copies/ml, respectively at year 5. Overall, 90% of patients had HBeAg seroconversion and only 10% had YMDD mutations. Conclusions: For HBeAg-positive patients with baseline HBV DNA<9 log10 copies/ml and ALT≥2xULN, lamivudine could be initiated. For those with HBV DNA<4 log10 copies/ml at week 4 or <3 log10 copies/ml at week 24, continuation of lamivudine treatment would be more likely to result in a good long-term response. © 2009 International Medical Press. | en_HK |
dc.language | eng | en_US |
dc.publisher | International Medical Press. The Journal's web site is located at http://www.intmedpress.com/Journals/AVT/journals_avt_home.cfm | en_HK |
dc.relation.ispartof | Antiviral Therapy | en_HK |
dc.subject.mesh | Adolescent | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Alanine Transaminase - Blood | en_US |
dc.subject.mesh | Dna, Viral - Blood | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Hepatitis B E Antigens - Blood | en_US |
dc.subject.mesh | Hepatitis B Virus - Drug Effects - Genetics | en_US |
dc.subject.mesh | Hepatitis B, Chronic - Drug Therapy - Virology | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Lamivudine - Administration & Dosage - Therapeutic Use | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle Aged | en_US |
dc.subject.mesh | Reverse Transcriptase Inhibitors - Administration & Dosage - Therapeutic Use | en_US |
dc.subject.mesh | Treatment Outcome | en_US |
dc.subject.mesh | Viral Load | en_US |
dc.subject.mesh | Young Adult | en_US |
dc.title | Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy | en_HK |
dc.type | Article | en_HK |
dc.identifier.email | Yuen, MF: mfyuen@hku.hk | en_HK |
dc.identifier.email | Fung, J: jfung@sicklehut.com | en_HK |
dc.identifier.email | Seto, WK: wkseto2@hku.hk | en_HK |
dc.identifier.email | Wong, DKH: danywong@hku.hk | en_HK |
dc.identifier.email | Lai, CL: hrmelcl@hku.hk | en_HK |
dc.identifier.authority | Yuen, MF=rp00479 | en_HK |
dc.identifier.authority | Fung, J=rp00518 | en_HK |
dc.identifier.authority | Seto, WK=rp01659 | en_HK |
dc.identifier.authority | Wong, DKH=rp00492 | en_HK |
dc.identifier.authority | Lai, CL=rp00314 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.pmid | 19704171 | - |
dc.identifier.scopus | eid_2-s2.0-69849093757 | en_HK |
dc.identifier.hkuros | 213677 | - |
dc.identifier.hkuros | 174348 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-69849093757&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 14 | en_HK |
dc.identifier.issue | 5 | en_HK |
dc.identifier.spage | 679 | en_HK |
dc.identifier.epage | 685 | en_HK |
dc.identifier.isi | WOS:000269719200009 | - |
dc.publisher.place | United Kingdom | en_HK |
dc.identifier.scopusauthorid | Yuen, MF=7102031955 | en_HK |
dc.identifier.scopusauthorid | Fung, J=23091109300 | en_HK |
dc.identifier.scopusauthorid | Seto, WK=23390675900 | en_HK |
dc.identifier.scopusauthorid | Wong, DKH=7401535819 | en_HK |
dc.identifier.scopusauthorid | Yuen, JCH=7102620480 | en_HK |
dc.identifier.scopusauthorid | Lai, CL=7403086396 | en_HK |
dc.identifier.issnl | 1359-6535 | - |